Antisense Oligonucleotides as Modulators of Pre-mRNA Splicing
Antisense oligonucleotides have been extensively used as downregulators of gene expression (1), and as such are not only increasingly used in various fields as sequence-specific research tools (2, 3, 4), but are also tested in clinical trials as antiviral and anticancer agents (5, 6, 7, 8).
KeywordsSplice Site Reverse Transcription Polymerase Chain Reaction Antisense Oligonucleotide Hank Balance Salt Solution Ammonium Persulfate
- 6.Bishop, M. R., Iversen, P. L., Bayever, E., Shar, J. G., Greiner, T. C., Copple, et al. (1995) Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol. 14, 1320–1326.Google Scholar
- 11.Weatherall, D. J. (1994) Thalassemias, in The Molecular Basis of Blood Diseases (Stamatoyannopoulos, G., et al., eds.), W.B. Saunders Philadelphia, pp. 157–205.Google Scholar
- 12.Mirabelli, C. K., and Crooke, S. T. (1993) Antisense oligonucleotides in the context of modern molecular drug discovery and development, in Antisense Research and Applications (Crooke, S. T. and Lebleu, B., eds.), CRC, Boca Raton, FL, pp. 7–35.Google Scholar
- 14.Sproat, B. S. and Lamond, A. I. (1993) 2′-O-alkyloligoribonucleotides, in Antisense Research and Applications (Crooke, S. T. and Lebleu, B., eds.), CRC, Boca Raton, FL, pp. 351–3Google Scholar
- 16.Hawley-Nelson, P., Ciccarone, V., Gebeyehu, G., Jessee, J., and Felgner, P. L. (1993) Lipofectamine reagent: a new, higher efficiency polycationic liposome transfection reagent. Focus 15, 73–79.Google Scholar